Tempest Therapeutics, Inc.
TPST Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$0.51
KIRA · Stoqly’s AI analyst, in plain words
- Tempest Therapeutics, Inc. lost $26.3M in fiscal 2025.
- Free cash flow was −$26.8M in fiscal 2025, — of revenue.
- Tempest Therapeutics, Inc. has $7.7M more cash than debt.
Market cap
$7.8M
P/E
—
Revenue
—
Net income
−$26.3M
Free cash flow
−$26.8M
Operating margin
—
Tempest Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$26.3M
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Tempest Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Tempest Therapeutics, Inc.
- CIK
- 0001544227
Tempest Therapeutics, Inc. · TPST
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$28.3M | −$35.7M | −$29.5M | −$41.8M | −$26.3M |
| Diluted EPS | −$7.47 | −$3.09 | −$1.91 | −$19.50 | −$6.33 |
| Cash | |||||
| Cash from operations | −$26.0M | −$31.1M | −$27.4M | −$33.0M | −$26.8M |
| Capital expenditure | $0.1M | $0.6M | $0.2M | $0.4M | $0.0M |
| Free cash flow | −$26.1M | −$31.6M | −$27.5M | −$33.5M | −$26.8M |
| Share count change | 709.5% | 204.7% | 33.5% | −86.1% | 93.3% |
| Debt and strength | |||||
| Cash and short-term investments | $51.8M | $31.2M | $39.2M | $30.3M | $7.7M |
| Debt incl. finance leases | $15.1M | $10.4M | $10.5M | $6.4M | $0.0M |
| Shareholders' equity | $36.1M | $18.1M | $26.8M | $19.1M | $6.7M |
| Current ratio | 3.4x | 4.5x | 4.3x | 2.2x | 2.5x |
| Interest coverage | −21.0x | −21.4x | −20.1x | −31.9x | −128.4x |
| Returns and quality | |||||
| Return on equity | — | −131.7% | −131.4% | −182.3% | −203.6% |
| Return on tangible equity | −78.4% | −197.2% | −110.2% | −218.8% | −393.9% |
| Piotroski F-score | 2 | 2 | 3 | 3 | 2 |
| Altman Z'' | −1.5 | −10.3 | −9.2 | −19.5 | −52.9 |
Insiders bought, 12 months
$1.0M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tempest Therapeutics, Inc. · TPST
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.51 a share, the company is worth $7.8M.
Source: SEC EDGAR XBRL filings (CIK 0001544227). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.